Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy

NCT07765446 is registered in ClinicalTrials.gov with Sironax USA, Inc. as lead sponsor.

NCT NCT07765446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07765446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy
Lead sponsor
Sironax USA, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 21, 2026
Completion date
December 31, 2027
Enrollment
18 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy